Sarepta's SiRNA Gambit: A High Stakes Bet on Gene Silencing Sarepta Therapeutics' second quarter earnings call offered a glimpse into the company's ambitious plans for its siRNA platform, but beneath the surface lies a complex web of risks and uncertainties.
The biotech industry continues to grapple with the promise and pitfalls of gene silencing, and Sarepta's strategic positioning is beginning to take shape.
The company's reliance on a "biology first" approach, selecting specific delivery architectures to overcome tissue specific barriers, sets it apart from its competitors.